Millennium Management’s Estrella Immunopharma ESLA Stock Holding History

Millennium Management’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,000	Closed	-$123K	–	6488
2022 Q4	$123K	Buy	12,000 +2,000	+20%	+$20.3K	﹤0.01%	5507
2022 Q3	$101K	Hold	10,000	–	–	﹤0.01%	5962
2022 Q2	$100K	Hold	10,000	–	–	﹤0.01%	5928
2022 Q1	$100K	Hold	10,000	–	–	﹤0.01%	6150
2021 Q4	$99K	Buy	+10,000	New	+$99.1K	﹤0.01%	6260

Other funds holding ESLA

HHGC

Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

RCM

Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

SOA

Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Millennium Management's ESLA Position: Q1 2023 in Review

Millennium Management sold out of Estrella Immunopharma (ESLA) in Q1 2023, closing a stake of 12,000 shares — an estimated $123K sold.

Millennium Management first reported a position in ESLA in Q4 2021 and held it in 5 quarters. The position peaked at $123K in Q4 2022. 8 funds tracked by Wall St. Rank hold ESLA as of Q1 2023.

Millennium Management reported no remaining Estrella Immunopharma position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 12,000 Estrella Immunopharma shares in Q1 2023, an estimated $123K.
Millennium Management first reported a position in Estrella Immunopharma in Q4 2021 and held it in 5 quarters.
Millennium Management's Estrella Immunopharma position peaked at $123K in Q4 2022.
8 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.